Okairos is pioneering the development of T-cell based vaccines for major infectious diseases, including hepatitis C, malaria, respiratory syncytial virus and influenza, as well as cancer.

Company Name

Okairos

Location

Basel, Switzerland

Investment Stage

Acquired by GSK for $325M in May 2013.